Tocqueville Asset Management L.P. Sells 3,359 Shares of Allergan plc (NYSE:AGN)
Tocqueville Asset Management L.P. lowered its position in shares of Allergan plc (NYSE:AGN) by 3.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 83,987 shares of the company’s stock after selling 3,359 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Allergan were worth $16,056,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Prestige Wealth Management Group LLC bought a new position in shares of Allergan during the 2nd quarter worth approximately $25,000. Old North State Trust LLC lifted its position in shares of Allergan by 172.4% during the 3rd quarter. Old North State Trust LLC now owns 158 shares of the company’s stock worth $27,000 after buying an additional 100 shares in the last quarter. Reilly Financial Advisors LLC lifted its position in shares of Allergan by 129.3% during the 3rd quarter. Reilly Financial Advisors LLC now owns 172 shares of the company’s stock worth $29,000 after buying an additional 97 shares in the last quarter. HM Payson & Co. bought a new position in shares of Allergan during the 2nd quarter worth approximately $29,000. Finally, Fusion Family Wealth LLC lifted its position in shares of Allergan by 81.4% during the 3rd quarter. Fusion Family Wealth LLC now owns 176 shares of the company’s stock worth $30,000 after buying an additional 79 shares in the last quarter. 82.28% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have commented on AGN shares. ValuEngine cut shares of Allergan from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th. UBS Group cut shares of Allergan from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $189.00 to $203.00 in a research report on Tuesday, November 19th. Finally, Wells Fargo & Co reissued an “outperform” rating and set a $184.00 target price (up previously from $176.00) on shares of Allergan in a research report on Monday, September 30th. One analyst has rated the stock with a sell rating, sixteen have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $175.90.
Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, November 5th. The company reported $4.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $4.25. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $3.88 billion. During the same period in the previous year, the business earned $4.25 EPS. Allergan’s revenue was up 2.9% compared to the same quarter last year. Sell-side analysts anticipate that Allergan plc will post 16.88 EPS for the current year.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Recommended Story: How prevalent are 12b-1 fees?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.